



## **REGENXBIO to Present at the Evercore ISI 2nd Annual HealthCONx Conference**

November 26, 2019 12:00 PM EST

ROCKVILLE, Md., Nov. 26, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV<sup>®</sup> Technology Platform, today announced it will present at the Evercore ISI 2<sup>nd</sup> Annual HealthCONx Conference on Tuesday, December 3, 2019, at 10:35 a.m. ET at the Four Seasons Hotel, Boston.

A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at [www.regenxbio.com](http://www.regenxbio.com). An archived replay of the fireside chat webcast will be available on the same website for approximately 30 days following the presentation.

### **About REGENXBIO Inc.**

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

### **Contacts:**

Tricia Truehart  
Investor Relations and Corporate Communications  
347-926-7709  
[ttruehart@regenxbio.com](mailto:ttruehart@regenxbio.com)

### **Investors:**

Heather Savelle, 212-600-1902  
[heather@argotpartners.com](mailto:heather@argotpartners.com)

### **Media:**

David Rosen, 212-600-1902  
[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)



 View original content to download multimedia: <http://www.prnewswire.com/news-releases/regenxbio-to-present-at-the-evercore-isi-2nd-annual-healthconx-conference-300964892.html>

SOURCE REGENXBIO Inc.